{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:18:43Z","timestamp":1762082323162,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003482","name":"John Wayne Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.amjsurg.2023.10.035","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:37:03Z","timestamp":1697542623000},"page":"258-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Is therapeutic lymph node dissection of value for lymph node recurrence in melanoma?"],"prefix":"10.1016","volume":"228","author":[{"given":"Ana K.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-5918","authenticated-orcid":false,"given":"Kristel","family":"Lourdault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Ostad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2146-8417","authenticated-orcid":false,"given":"Richard","family":"Essner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjsurg.2023.10.035_bib1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","article-title":"Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial","volume":"242","author":"Morton","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib3","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","article-title":"Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases","volume":"24","author":"Faries","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib4","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib6","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines","volume":"19","author":"Swetter","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib9","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41379-021-00835-5","article-title":"The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma","volume":"10","author":"Kretschmer","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib10","first-page":"1145","article-title":"Survival in patients with sentinel node-positive melanoma with extranodal extension","volume":"10","author":"Maurichi","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(97)08260-3","article-title":"Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial","volume":"351","author":"Cascinelli","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib12","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Jens Ulrich","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib13","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1245\/s10434-020-09277-w","article-title":"Characterization of sentinel lymph node immune signatures and implications for risk stratification for adjuvant therapy in melanoma","volume":"28","author":"Farrow","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib14","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1245\/s10434-021-09595-7","article-title":"ASO author reflections: gene expression-profiling and implications for adjuvant therapy in melanoma","volume":"7","author":"Farrow","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11912-019-0798-y","article-title":"Sentinel lymph node biopsy and complete lymph node dissection for melanoma","volume":"21","author":"Falk Delgado","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib16","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.cell.2022.04.019","article-title":"Lymph node colonization induces tumor-immune tolerance to promote distant metastasis","volume":"185","author":"Reticker-Flynn","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib17","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/cncr.32162","article-title":"An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma","volume":"125","author":"Najjar","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib19","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.hoc.2009.03.006","article-title":"The history and future of chemotherapy for melanoma","volume":"23","author":"Yang","year":"2009","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.clindermatol.2012.08.015","article-title":"Historical review of melanoma treatment and outcomes","volume":"31","author":"Lee","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib22","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?","volume":"40","author":"Eggermont","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.1984.2.3.164","article-title":"Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma","volume":"2","author":"Luikart","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib25","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib27","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.amjsurg.2023.10.035_bib28","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961023005640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961023005640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:14:25Z","timestamp":1762082065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961023005640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":28,"alternative-id":["S0002961023005640"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2023.10.035","relation":{},"ISSN":["0002-9610"],"issn-type":[{"type":"print","value":"0002-9610"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is therapeutic lymph node dissection of value for lymph node recurrence in melanoma?","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2023.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}